Recent Company News

• 04:15 PM ET Apr 24, 2025
  

  Inventiva announces publication in Clinical Gastroenterology and Hepatology (€3.16, 0.00)

• 10:09 AM ET Apr 22, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (36 total)

• 05:01 PM ET Apr 01, 2025
  

  Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis (€2.78, 0.00)

• 04:02 PM ET Mar 26, 2025
  

  Inventiva reports FY revenue €9.2M vs FactSet €8.5M [7 est, €2.8-13.3M] (€2.75, 0.00)

• 04:07 PM ET Feb 26, 2025
  

  Inventiva publishes results from preclinical study demonstrating that lanifibranor may reduce portal hypertension (€2.99, 0.00)

• 08:06 AM ET Feb 21, 2025
  

  Inventiva initiated buy at TD Cowen ($2.74, 0.00)

• 04:16 PM ET Feb 20, 2025
  

  Inventiva doses first patient in Phase 1 trial evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of lanifibranor (€2.42, 0.00)

• 04:04 PM ET Feb 10, 2025
  

  Inventiva reports preliminary FY 2024 revenue €9.2M vs FactSet €7.7M; provides business update (€2.27, 0.00)

• 09:21 AM ET Jan 30, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 08:27 AM ET Jan 30, 2025
  

  StreetAccount Summary - US Pre-market trading